Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Broker tips: Hochschild, Fresnillo, Synthomer

(Sharecast News) - RBC Capital Markets upgraded Hochschild but downgraded Fresnillo on Thursday as it took a look at European miners, revising its commodity price assumptions. Hochschild was lifted to 'outperform' from 'sector perform' and its target price was increased to 270.0p from 260.0p.

RBC noted that Hochschild has underperformed gold and silver miners by 20% year to date, making it the most inexpensive silver company in its coverage.

"Although we think the path to outperformance will be harder this year, we see risk-reward levels as attractive following the rebasement in the group valuation and consensus forecasts and we upgrade our rating," it said, as it noted Hochschild was its preferred exposure in the precious metals space.

As far as Fresnillo was concerned, RBC downgraded the stock to 'sector perform' from 'outperform' and lifted its price target to on the stock to 880.0p from 810.0p.

The Canadian bank noted that Fresnillo has outperformed silver peers by 20% year to date, helped by strong price/operational momentum and the weakening of the Mexican Peso.

"We see potential for further rerating as margins expand in the coming two years but see upside more limited following recent outperformance," it admitted, but added that it sees better risk-reward in other silver companies.

Analysts at Berenberg downgraded speciality chemicals firm Synthomer from 'buy' to 'hold' on Thursday and cut its target price on the stock from 230.0p to 150.0p, stating the "margin of safety" was now "too thin".

Berenberg said downgrading its recommendation for Synthomer at the trough of its earnings cycle was "disheartening", but noted that the alternative was potentially worse.

"Waiting through a prolonged trough during which even minor additional cuts to earnings forecasts could move leverage from uncomfortable to precarious," said Berenberg.

The German bank stated the main factors that could have significantly improved the margin of safety were, in its view, a quick recovery in nitrile latex and divestments. However, it said neither seems as compelling as a few months ago.

"The circa 5% cuts to our adjusted EBITDA estimates for 2025/26 primarily reflect lower margins in nitrile latex and more subdued performance in the energy business. Our 2025 EBITDA estimates are circa 8% below Bloomberg consensus," added Berenebrg.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.